Adaptive responses to SARS-CoV-2 variants in the context of hybrid immunity and immune impairment

Grant number: 226137/Z/22/Z

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2023
    2025
  • Known Financial Commitments (USD)

    $3,852,733.63
  • Funder

    Wellcome Trust
  • Principal Investigator

    Prof Alexander Sigal
  • Research Location

    South Africa
  • Lead Research Institution

    Africa Health Research Institute
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SARS-CoV-2 evolved variants that could escape previous immunity and transmit better. This process so far culminated in the Omicron variant, which led to a global infection wave of unprecedented scale. To ensure an effective response to variants, their biology, evolution, and mechanisms of escape must be better understood. It is critical to rapidly determine cross-protection afforded by vaccination or previous infections against emerging variants and understand the mechanisms for that protection or lack thereof. This will require understanding B and T cell targets, as well as how these relate to emerging variation, to quickly model/predict new viral escape mutations. Such a high- resolution response is only possible by combining immunology, virology, T and B cell biology, antibody mapping, and structural biology, and will need to be done for increasingly hybrid-induced immunity. The effort must also benefit young investigators. Specific Aims 1. Perform immunological surveillance of current and emerging variants and predict future mutations which impact antibody and T cell immunity 2. Determine how increasingly complex hybrid immunity functions against current and emerging variants 3. Determine how immune impairment mediated by co-infection with HIV modulates response to variants 4. Promote the next generation of African scientists through cutting- edge research and scientific exchange

Publicationslinked via Europe PMC

Last Updated:38 minutes ago

View all publications at Europe PMC

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

SARS-CoV-2 correlates of protection from infection against variants of concern.

SARS-CoV-2 correlates of protection from infection against variants of concern

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation.

Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV.

Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant.

Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivity.

SARS-CoV-2 infection in immunosuppression evolves sub-lineages which independently accumulate neutralization escape mutations.